Melanonychia and mucocutaneous hyperpigmentation from hydroxyurea use for the treatment of essential thrombocytosis
Singapore medical journal
;
: e7-8, 2014.
Article
in English
| WPRIM
| ID: wpr-337794
ABSTRACT
Hydroxyurea is an antineoplastic agent commonly used to treat essential thrombocytosis. We report the case of a 50-year-old woman who was incidentally detected to have essential thrombocytosis after suffering an episode of cerebrovascular accident with faciobrachial monoparesis. She was subsequently initiated on hydroxyurea. Within seven weeks of therapy, the patient noticed irregular hyperpigmented patches over her feet, hands and perioral region, with bluish-grey longitudinal bands on all 20 nails. Hydroxyurea-induced hyperpigmentation and melanonychia are not commonly reported. To the best of our knowledge, this is only the third published report of hydroxyurea-induced hyperpigmentation and melanonychia involving all 20 nails. Physicians need to be aware of such mucocutaneous side effects to avoid misdiagnosis and unwarranted fear in patients. The decision to discontinue the intake of the drug depends heavily on the future risk of thrombotic events.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Thrombocytosis
/
Treatment Outcome
/
Hyperpigmentation
/
Stroke
/
Therapeutic Uses
/
Drug Therapy
/
Hydroxyurea
/
Nail Diseases
/
Nails
Type of study:
Prognostic study
Limits:
Female
/
Humans
Language:
English
Journal:
Singapore medical journal
Year:
2014
Type:
Article
Similar
MEDLINE
...
LILACS
LIS